- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04123379
Neoadjuvant nivolumab met CCR2/5-remmer of anti-IL-8) voor niet-kleincellige longkanker (NSCLC) of hepatocellulair carcinoom (HCC)
Tisch Cancer Institute - BMS-onderzoek # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-remmer) of BMS-986253 (Anti-IL-8) voor NSCLC of HCC
The purpose of this research study is to study the effect of giving nivolumab with CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining if this medicine results in:
- A significant immune response against their tumor (which the study team will see in the tumor that is taken out at the time of surgery)
- Improvement in long term survival rates
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Objectives:
Cohorts A,B (NSCLC):
Primary Objective: Major Pathologic Response (MPR) Secondary Objectives: Time to surgery, tolerability and safety, radiographic response
Cohorts C,D,E (HCC):
Primary Objective: Significant tumor necrosis (STN) Secondary Objectives: Time to surgery, tolerability and safety, radiographic response
Diagnosis and Main Inclusion Criteria:
Patients must have disease deemed resectable before enrollment.
Study Product:
Nivolumab 480mg (q4w, dosed twice before surgery and three times following recovery from surgery) BMS-813160 (CCR2/5-inhibitor) 300mg oral twice a day for 28 days BMS-986253 (anti-IL-8) 2400mg once
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosis of NSCLC or HCC
- Willing to provide blood samples
- Willing to undergo leukapheresis at Mount Sinai Hospital or New York Blood Bank
- Willing to have excisional or core needle biopsies
- At least 18 years of age
- ECOG 0-1
- Surgical candidate for resection of their tumor
- Agree to use adequate contraception
- Adequate organ and marrow function
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 months for a different primary tumor or patients who have received locoregional therapy for the target lesion
- Patients receiving any other investigational agents
- Patients with metastatic disease for whom the intent of surgery would not be curative
- Uncontrolled intercurrent illness
- Pregnant or nursing
- Has a diagnosis of primary immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days
- Has active autoimmune disease that has required systemic treatment in the past year
- Has a known additional malignancy that is progressing and/or requires active treatment
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not the in the best interest of the patient to participate
- HIV positive with detectable viral load or anyone not on stable anti-viral regimen
- Has known active Hepatitis B
- History of allogeneic hematopoietic cell transplantation or solid organ transplantation
- Documented allergic or hypersensitivity response to any protein therapeutics
- Patients may not have prolonged QRS or QTc
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Cohort A
NSCLC: Nivolumab + BMS-813160 |
q4w, dosed twice before surgery and three times following recovery from surgery by injection 300mg oral twice a day for 28 days
Andere namen:
|
|
Experimenteel: Cohort B
NSCLC: Nivolumab + BMS-986253 |
q4w, dosed twice before surgery and three times following recovery from surgery by injection 2400mg once by injection
Andere namen:
|
|
Experimenteel: Cohort C
HCC: Nivolumab |
q4w, dosed twice before surgery and three times following recovery from surgery by injection |
|
Experimenteel: Cohort D
HCC: Nivolumab + BMS-813160 |
q4w, dosed twice before surgery and three times following recovery from surgery by injection 300mg oral twice a day for 28 days
Andere namen:
|
|
Experimenteel: Cohort E
HCC: Nivolumab + BMS-986253 |
q4w, dosed twice before surgery and three times following recovery from surgery by injection 2400mg once by injection
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Major Pathologic Response (MPR)
Tijdsspanne: 2 Years
|
MPR is defined as <10% viable tumor within resection, at time of surgery. |
2 Years
|
|
Significant Tumor Necrosis (STN)
Tijdsspanne: 2 Years
|
STN is defined as necrosis of >70% of tumor base on pathologic analysis of gross tumor resection at time of surgery. |
2 Years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to Surgery
Tijdsspanne: 2 Years
|
Measured as the time in days that elapses between the first dose of neoadjuvant therapy and surgical resection. |
2 Years
|
|
Percent of individuals who experience adverse events
Tijdsspanne: 2 Years
|
Safety and Tolerability defined by the percent of individuals who experience adverse events at any point during the neoadjuvant period, or within 30 days following the final dose of nivolumab received. |
2 Years
|
|
Percent of individuals who experience radiographic response
Tijdsspanne: 2 Years
|
As per RECIST v1.1 as determined by pre-surgical imaging, following receipt of the neoadjuvant therapy. For NSCLC this will be based on CT imaging, while for HCC this imaging will be based on MRI radiographic post-contract subtraction. |
2 Years
|
|
Progression-free survival (PFS)
Tijdsspanne: 2 Years
|
Defined as the time, in days, between treatment initiation and when the patient is found to have recurrent and/or metastatic disease on imaging, or death for any reason. |
2 Years
|
|
Overall Survival (OS)
Tijdsspanne: 5 Years
|
Defined as the time, in days, between treatment initiation and when the patient dies from any cause regardless of etiology. |
5 Years
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Thomas Marron, MD PhD, Icahn School of Medicine at Mount Sinai
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Longziekten
- Lever Ziekten
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Lever neoplasmata
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Longneoplasmata
- Carcinoom
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Carcinoom, hepatocellulair
- Carcinoom, niet-kleincellige long
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Nivolumab
- Humax-IL8
- BMS-813160
Andere studie-ID-nummers
- GCO 19-1754
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .